US challenges GlaxoSmithKline over earnings stripping

The US Internal Revenue Service (IRS) is battling the UK-based pharmaceuticals company GlaxoSmithKline over a potential $1.9 billion in back taxes, interest and penalties.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: